Network Meta-analysis Shows Commercialized Subcutaneous and Sublingual Grass Products Have Comparable Efficacy

Journal of Allergy and Clinical Immunology: In Practice

Volumn 3, Issue 2, 2015, Pages 256-266.e3

  Nelson, Harold ^a   Cartier, Shannon ^b   Allen Ramey, Felicia ^c   Lawton, Simon ^d   Calderon, Moises A ^e  

^a DEPARTMENT OF MEDICINE   (United States)

^b OPTUM   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d ALK Horsholm   (Denmark)

^e ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Allergen immunotherapy; Grass pollen; Immunotherapy; Meta analysis; Subcutaneous immunotherapy; Sublingual immunotherapy

Indexed keywords

ARTICLE; COMPARATIVE EFFECTIVENESS; HUMAN; META ANALYSIS; POLLEN ALLERGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOCONJUNCTIVITIS; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SYSTEMATIC REVIEW; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION; IMMUNOLOGY; POACEAE; PROCEDURES; RHINITIS, ALLERGIC, SEASONAL; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, SUBLINGUAL; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; HUMANS; INJECTIONS, SUBCUTANEOUS; POACEAE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 84924096286     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2014.09.018     Document Type: Article

References (63)

1. Meltzer E.O., Blaiss M.S., Naclerio R.M., Stoloff S.W., Derebery M.J., Nelson H.S., et al. Burden of allergic rhinitis: allergies in America, Latin America, and Asia-Pacific adult surveys. Allergy Asthma Proc 2012, 33:S113-S141.
2. Schwindt C.D., Settipane R. Allergic rhinitis (AR) is now estimated to affect some 1.4 billion people globally and continues to be on the rise: editorial. Am J Rhinol Allergy 2012, 26:S1.
3. White book onallergy 2011-2012 executive summary 2011, World Allergy Organization, Milwaukee, Wis. R. Pawankar, G.W. Canonica, S.T. Holgate, R.F. Lockey (Eds.).
4. Nathan R.A., Meltzer E.O., Derebery J., Campbell U.B., Stang P.E., Corrao M.A., et al. The prevalence of nasal symptoms attributed to allergies in the United States: findings from the burden of rhinitis in an America survey. Allergy Asthma Proc 2008, 29:600-608.
5. Meltzer E., Blaiss M., Derebery M., Boyle J., Naclerio R., Hadley J., et al. Perspectives on allergic rhinitis and its treatment. Allergy Asthma Proc 2007, 28:S1-32.
6. Meltzer E.O., Blaiss M.S., Derebery M.J., Mahr T.A., Gordon B.R., Sheth K.K., et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. JAllergy Clin Immunol 2009, 124:S43-70.
7. Bauchau V., Durham S.R. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004, 24:758-764.
8. White P., Smith H., Baker N., Davis W., Frew A. Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy?. Clin Exp Allergy 1998, 28:266-270.
9. Walker S.M., Durham S.R., Till S.J., Roberts G., Corrigan C.J., Leech S.C., et al. Immunotherapy for allergic rhinitis. Clin Exp Allergy 2011, 41:1177-1200.
10. Cox L., Nelson H., Lockey R., Calabria C., Chacko T., Finegold I., et al. Allergen immunotherapy: a practice parameter third update. JAllergy Clin Immunol 2011, 127:S1-55.
11. Cox L., Calderon M.A. Subcutaneous specific immunotherapy for seasonal allergic rhinitis: a review of treatment practices in the US and Europe. Curr Med Res Opin 2010, 26:2723-2733.
12. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD001936. http://dx.doi.org/10.1002/14651858.CD001936.pub2.
13. Radulovic S., Wilson D., Calderon M., Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011, 66:740-752.
14. Lin S.Y., Erekosima N., Kim J.M., Ramanathan M., Suarez-Cuervo C., Chelladurai Y., et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA 2013, 309:1278-1288.
15. Purkey M.T., Smith T.L., Ferguson B.J., Luong A., Reisacher W.R., Pillsbury H.C., et al. Subcutaneous immunotherapy for allergic rhinitis: an evidence based review of the recent literature with recommendations. Int Forum Allergy Rhinol 2013, 3:519-531.
16. Di Bona D., Plaia A., Leto-Barone M.S., La P.S., Di L.G. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. JAllergy Clin Immunol 2012, 130:1097-1107.
17. Dretzke J., Meadows A., Novielli N., Huissoon A., Fry-Smith A., Meads C. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. JAllergy Clin Immunol 2013, 131:1361-1366.
18. Chelladurai Y., Suarez-Cuervo C., Erekosima N., Kim J.M., Ramanathan M., Segal J.B., et al. Effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAllergy Clin Immunol Pract 2013, 1:361-369.
19. Kim J.M., Lin S.Y., Suarez-Cuervo C., Chelladurai Y., Ramanathan M., Segal J.B., et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics 2013, 131:1155-1167.
20. National Institute for Health and Care Excellence (NICE). Process and methods guides. The guidelines manual: appendices B -I. Published: 30 November 2012. Appendix C: Methodological Checklist: randomised controlled trials Accessed November 10, 2014. http://www.nice.org.uk/article/pmg6b/chapter/appendix-c-methodology-checklist-randomised-controlled-trials.
21. Review Manager (RevMan) 2011, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen.
22. Lunn D.J., Thomas A., Best N., Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000, 10:325-337.
23. Jansen J.P., Fleurence R., Devine B., Itzler R., Barrett A., Hawkins N., et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011, 14:417-428.
24. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from http://www.cochrane-handbook.org.
25. Spiegelhalter D.J., Myles J.P., Jones D.R., Abrams K.R. Methods in health service research: an introduction to Bayesian methods in health technology assessment. BMJ 1999, 319:508-512.
26. Bufe A., Eberle P., Franke-Beckmann E., Funck J., Kimmig M., Klimek L., et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. JAllergy Clin Immunol 2009, 123:167-173.
27. Didier A., Malling H., Worm M., Horak F., Jager S., Montagut A., et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. JAllergy Clin Immunol 2007, 120:1338-1345.
28. Durham S.R., Yang W.H., Pedersen M.R., Johansen N., Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. JAllergy Clin Immunol 2006, 117:802-809.
29. Wahn U., Tabar A., Kuna P., Halken S., Montagut A., de B.O., et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. JAllergy Clin Immunol 2009, 123:160-166.
30. Dahl R., Stender A., Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006, 61:185-190.
31. Dahl R., Kapp A., Colombo G., de Monchy Jan G.R., Rak S., Emminger W., et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. JAllergy Clin Immunol 2006, 118:434-440.
32. Blaiss M., Maloney J., Nolte H., Gawchik S., Yao R., Skoner D.P. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. JAllergy Clin Immunol 2011, 127:64-71. 71.e1-4.
33. Nelson H.S., Nolte H., Creticos P., Maloney J., Wu J., Bernstein D.I. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. JAllergy Clin Immunol 2011, 127:72-80. 80.e1-2.
34. Caffarelli C., Sensi L.G., Marcucci F., Cavagni G. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy 2000, 55:1142-1147.
35. Horak F., Zieglmayer P., Zieglmayer R., Lemell P., Devillier P., Montagut A., et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. JAllergy Clin Immunol 2009, 124:471-477. 477.e1.
36. Mosges R., Bruning H., Hessler H.-J., Gotz G., Knaussmann H.-G. Sublingual immunotherapy in pollen-induced seasonal rhinitis and conjunctivitis: a randomized controlled trial. Acta Dermatovenerol Alp Panonica Adriat 2007, 16:143-148.
37. Cox L., Casale T.B., Nayak A., Creticos P., Montagut A., Zeldin R.K. AUS study of 5-grass pollen allergen extract in adults with grass pollen-induced allergic rhinoconjunctivitis-results of secondary efficacy assessments. JAllergy Clin Immunol 2012, 129:AB46.
38. Murphy K., Gawchik S., Bernstein D., Pedersen M.R., Andersen J. Aphase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma. JNegat Results BioMed 2013, 12:10.
39. Maloney J., Bernstein D.I., Nelson H., Creticos P., Hébert J., Noonan M., et al. Efficacy and safety of grass allergy immunotherapy tablet (AIT) treatment in a large randomized controlled trial in North American children and adults. Ann Allergy Asthma Immunol 2014, 112:146-153.
40. Rolinck-Werninghaus C., Wolf H., Liebke C., Baars J.C., Lange J., Kopp M.V., et al. Aprospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy 2004, 59:1285-1293.
41. Bufe A., Ziegler-Kirbach E., Stoeckmann E., Heidemann P., Gehlhar K., Holland-Letz T., et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 2004, 59:498-504.
42. Pfaar O., Klimek L. Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol 2008, 100:256-263.
43. Hordijk G.J., Antvelink J.B., Luwema R.A. Sublingual immunotherapy with a standardised grass pollen extract: a double-blind placebo-controlled study. Allergol Immunopathol (Madr) 1998, 26:234-240.
44. de Blay F., Barnig C., Kanny G., Purohit A., Leynadier F., Tunon de Lara J.M., et al. Sublingual-swallow immunotherapy with standardized 3-grass pollen extract: a double-blind, placebo-controlled study. Ann Allergy Asthma Immunol 2007, 99:453-461.
45. Lima M.T., Wilson D., Pitkin L., Roberts A., Nouri-Aria K., Jacobson M., et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002, 32:507-514.
46. Ott H., Sieber J., Brehler R., Folster-Holst R., Kapp A., Klimek L., et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 2009, 64:1394-1401.
47. Feliziani V., Lattuada G., Parmiani S., Dall'Aglio P.P. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts: a double blind study. Allergol Immunopathol 1995, 23:224-230.
48. Amar S.M., Harbeck R.J., Sills M., Silveira L.J., O'Brien H., Nelson H.S. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. JAllergy Clin Immunol 2009, 124:150-156.
49. Clavel R., Bousquet J., Andre C. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 1998, 53:493-498.
50. Panzner P., Petras M., Sykora T., Lesna I. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually. Respir Med 2008, 102:1296-1304.
51. Stelmach I., Kaczmarek-Wozniak J., Majak P., Olszowiec-Chlebna M., Jerzynska J. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp Allergy 2009, 39:401-408.
52. Stelmach I., Kaluzinska-Parzyszek I., Jerzynska J., Stelmach P., Stelmach W., Majak P. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children. Allergy 2012, 67:312-320.
53. Wahn U., Klimek L., Ploszczuk A., Adelt T., Sandner B., Trebas P.E. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study. JAllergy Clin Immunol 2012, 130:886-893.
54. Walker S.M., Pajno G.B., Lima M.T., Wilson D.R., Durham S.R. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. JAllergy Clin Immunol 2001, 107:87-93.
55. Corrigan C.J., Kettner J., Doemer C., Cromwell O., Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 2005, 60:801-807.
56. Drachenberg K.J., Wheeler A.W., Stuebner P., Horak F. Awell-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001, 56:498-505.
57. Frew A.J., Powell R.J., Corrigan C.J., Durham S.R. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. JAllergy Clin Immunol 2006, 117:319-325.
58. Varney V.A., Gaga M., Frew A.J., Aber V.R., Kay A.B., Durham S.R. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991, 302:265-269.
59. Zenner H.P., Baumgarten C., Rasp G., Fuchs T., Kunkel G., Hauswald B., et al. Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. JAllergy Clin Immunol 1997, 100:23-29.
60. Kuna P., Alam R., Kuzminska B., Rozniecki J. The effect of preseasonal immunotherapy on the production of histamine-releasing factor (HRF) by mononuclear cells from patients with seasonal asthma: results of a double-blind, placebo-controlled, randomized study. JAllergy Clin Immunol 1989, 83:816-824.
61. DuBuske L.M., Frew A.J., Horak F., Keith P.K., Corrigan C.J., Aberer W., et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc 2011, 32:239-247.
62. Pfaar O., Urry Z., Robinson D.S., Sager A., Richards D., Hawrylowicz C.M., et al. Arandomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy 2012, 67:272-279.
63. Durham S.R., Nelson H.S., Nolte H., Bernstein D.I., Creticos P.S., Li Z., et al. Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure. Allergy 2014, 69:617-623.